NCT06774157

Brief Summary

The goal of this clinical study is to determine the effectiveness of restoring muscle strength in the management of motor inhibition when complemented by the ALLYANE process (neuro-motor reprogramming) compared to a standard management approach. The main questions it aims to answer are:

  • Does the ALLYANE process lead to greater muscle strength gains compared to standard care?
  • Is there a functional benefit when standard management is complemented by the ALLYANE process? The investigators will compare the group receiving standard care complemented by ALLYANE to a group receiving only standard care to evaluate if the ALLYANE process provides additional effects. Participants will:
  • Undergo assessments of muscle strength.
  • Receive either standard management or standard management with ALLYANE.
  • Complete functional evaluations before and after treatment.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started Jan 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Jan 2024Dec 2026

Study Start

First participant enrolled

January 15, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

October 7, 2024

Completed
3 months until next milestone

First Posted

Study publicly available on registry

January 14, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2026

Last Updated

March 7, 2025

Status Verified

March 1, 2025

Enrollment Period

2.9 years

First QC Date

October 7, 2024

Last Update Submit

March 5, 2025

Conditions

Keywords

AMIALLYANElow frequency soundsmotor imagery

Outcome Measures

Primary Outcomes (1)

  • Muscle activity

    Electromyography (EMG) during maximal voluntary isometric contraction of leg extension.

    Before and 3 weeks after conventional therapy

Secondary Outcomes (1)

  • Strength

    Before and 3 weeks after conventional therapy

Other Outcomes (1)

  • Lysholm Questionnaire

    Before and 3 weeks after conventional therapy.

Study Arms (2)

Standard Management

ACTIVE COMPARATOR

This group of patients will receive the conventional approach for managing motor inhibitions, which may include traditional physical therapy, exercises, and other rehabilitative techniques without any additional intervention.

Other: Standard management - Control group

Standard Management + ALLYANE Process

EXPERIMENTAL

This group will receive the same standard management as the first group but with the addition of the ALLYANE process, a neuro-motor reprogramming technique designed to enhance muscle activation and re-establish motor control.

Other: A session combining motor imagery and listening to low frequency soundsOther: Standard management - Control group

Interventions

Prospective study of the efficacy of the Allyane procedure after knee sprain

Also known as: ALLYANE, Motor imagery, low frequency sounds
Standard Management + ALLYANE Process

Active extension (e.g. by lateral raising of the quadriceps, strengthening of the quadriceps) quadriceps)

Standard ManagementStandard Management + ALLYANE Process

Eligibility Criteria

Age18 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Men and women aged 18 to 35 years
  • No neurological history
  • Have had a primary knee sprain
  • Present with VMO lateralisation with or without the presence of flessum
  • Quadricipital weakness between the healthy and injured limb of 50% or more as measured by a portable dynamometer
  • Member of a social security scheme

You may not qualify if:

  • Recurrent sprain
  • Bilateral sprain
  • Persons under guardianship, trusteeship or any other measure depriving them of their rights or liberty, and adults protected by law.
  • Persons who do not understand French
  • Knee trauma other than sprain
  • Algodystrophy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Expert du Mouvement

Lyon, 69004, France

Location

Related Publications (1)

  • Dos Anjos T, Gabriel F, Vieira TD, Hopper GP, Sonnery-Cottet B. Neuromotor Treatment of Arthrogenic Muscle Inhibition After Knee Injury or Surgery. Sports Health. 2024 May-Jun;16(3):383-389. doi: 10.1177/19417381231169285. Epub 2023 Apr 27.

    PMID: 37102673BACKGROUND

Related Links

Study Officials

  • Aymeric Guillot, Pr

    Laboratoire Interuniversitaire de Biologie de la Motricité

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 7, 2024

First Posted

January 14, 2025

Study Start

January 15, 2024

Primary Completion (Estimated)

December 20, 2026

Study Completion (Estimated)

December 20, 2026

Last Updated

March 7, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

The shared IPD will include key data points such as demographic information, muscle strength assessment results, functional evaluation scores, and patient-reported outcomes like Lysholm Questionnaire results. Personal identifiers will be removed to ensure participant confidentiality. Data sharing will adhere to ethical and legal requirements. Specifically, the individual participant data sets underlying results in a publication will be shared.

Shared Documents
STUDY PROTOCOL
Time Frame
The IPD and supporting information will be made available starting after statistical analysis is complete and during the process of writing the manuscript for publication. The data will remain accessible for a period of three years following the publication of the study results.
Access Criteria
Access to the IPD and supporting information will be granted to qualified researchers affiliated with academic, governmental, or non-profit institutions. They will have access to de-identified individual participant data, including demographic details, muscle strength assessments, functional evaluation results, and patient-reported outcomes. Access will be provided through a secure repository or data-sharing platform after approval of a data-sharing agreement. Researchers must agree to use the data solely for academic and non-commercial purposes, comply with all ethical guidelines, and acknowledge the source in any resulting publications.

Locations